Targeting LSD1 Epigenetic Signature in Castration-Recurrent Prostate Cancer
Annual rept. 30 Sep 2013-29 Sep 2014
HEALTH RESEARCH INC BUFFALO NY
Pagination or Media Count:
Prostate cancer PCa is the second most common cause of cancer death in men in the US. PCa is initially driven by circulating androgens that activate AR and its downstream targets. AR inhibition is a primary therapeutic intervention but patients often relapse and develop castration recurrent PCa CRPCa. This is often clinically lethal. Here we describe a potential therapeutic approach for patients that develop CRPCa. We demonstrated that targeting AR and its coregulator LSD1 lead to additive antiproliferative effect in-vitro and potentially reduces CRPCa progression in-vivo. Ongoing studies aim to describe the genome-wide signature of AR and LSD1 in androgen responsive and CRPCa cell lines, in addition to cell lines with DHT-activated AR. Validation of this approach in our pre-clinical studies can have a beneficial impact on PCa patients since it defines a novel therapeutic regiment that relies on already clinically available drugs.
- Medicine and Medical Research